Lucid Diagnostics Inc.(LUCD)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Lucid Diagnostics Inc. (LUCD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LUCD at 29.5/100 on a 32-signal composite quality model, placing it at rank #2,528 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Lucid Diagnostics Inc. reports quarterly revenue of $1.5M, net income of $-11.7M, free cash flow of $-11.3M. Top institutional holders of LUCD by reported 13-F value include Alyeska Investment Group, L.P., BlackRock, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LUCD trades on the Nasdaq exchange and files with the SEC under CIK 1799011. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LUCD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Lucid Diagnostics Inc. directly from SEC EDGAR.